摘要
目的调查分析东北地区2006-2007年临床分离细菌对抗菌药物的耐药性。方法2006年6月1日-2007年5月31日，东北地区9家医院收集临床分离细菌，并进行药敏试验，结果依据2006年CLSI标准，采用WHONET5．4软件进行统计分析。结果9195株细菌中革兰阴性菌6814株，占74．1％，革兰阳性菌2381株，占25．9％。大肠埃希菌、肺炎克雷伯菌和奇异变形菌ESBLs的发生率分别为43．7％、38．3％和7．0％。MRSA和MRCNS检出率分别为64．8％和76．5％，未检测到万古霉素耐药株，也未发现万古霉素、替考拉宁耐药的粪肠球菌和屎肠球菌。亚胺培南对肠杆菌科细菌仍保持较高的敏感性（〉94％）。大约68％的大肠埃希菌对环丙沙星及左氧氟沙星耐药。铜绿假单胞菌对头孢哌酮／舒巴坦耐药性最低（19．7％），其次是阿米卡星、环丙沙星、头孢他啶、亚胺培南和头孢噻肟（21．4％～31．3％）；鲍曼不动杆菌对亚胺培南敏感率可达84．4％。结论对细菌耐药性应引起足够重视，加强抗菌药物合理使用以降低耐药性，并采取有效措施控制其传播。
Objective The aim of this study was to investigate the antibiotic resistance in clinical isolates in 2006-2007. Methods From June 1 2006 to May 31 2007, consecutive and non-repetitive clinical isolates were collected in 9 hospitals from northeast region, and antimicrobial susceptibility testing was carried out. The data were analyzed by WHONET 5.4 software. Results Of the 9195 clinical isolates collected, 74.1% were Gram-negative bacilli and 25.9% were Gram-positive cocci. About 64.8% of Staphylococcus aureus were methicillin-resistant （MRSA）, and 76.5% of coagulase negative Staphylococcus isolates were methicillin-resistant （MRCNS）. No vancomycin or teicoplanin-resistant isolates were found in Staphylococcus, Enterococcus faecal and Enterococcus faecium. The prevalence of extended-spectrum β-1actamases （ESBLs） was 43.7% in E. coli, 38.3% in K. pneumoniae and 7.0% in Proteus mirabilis. About 68% of E. coli isolates were resistant to ciprofloxacin and levofloxacin. Imipenem was the most potent antimicrobial agents against Enter-obacteriaceae （〉94 %）. The lowest resistance rate of P. aeruginosa was 14.7% （cefoperazone/sulbactam）, followed by amikacin, ceftazidime, ciprofloxacin, cefotaxime and imipenem （21.4%-31.3%）, while more than 84.4% of the A. baumannii isolates were susceptible to imipenem. Conclusions It was very important to rationally use antimicrobial agents and take effective measures for the control of the spread of resistant isolates.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2008年第10期640-646,共7页
Chinese Journal of Antibiotics
